Concepedia

BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

Alexander G.G. Turpie, W. D. Fisher, Kenneth A. Bauer, Lana Kwong, M.W. IRWIN, Peter Kälebo, Frank Misselwitz, Michael Gent

Journal of Thrombosis and Haemostasis · 2005 · 301 citations · 13 references

DOIFull text

Open access

Concepts

References

13

Roentgen Diagnosis of Venous Thrombosis in the Leg

Keith Rabinov · Archives of Surgery · 1972 · 760 citations

, , +17

Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery

Kenneth A. Bauer, Bengt I. Eriksson, Michael R. Lassen et al. · New England Journal of Medicine · 2001 · 661 citations · Full text

, , +15

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor

Elisabeth Perzborn, Andreas Wilmen, Jens Pohlmann et al. · Journal of Thrombosis and Haemostasis · 2005 · 584 citations · Full text

, , +12

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial

Bengt I. Eriksson, O.E. Dahl, Harry R. Büller et al. · Journal of Thrombosis and Haemostasis · 2004 · 413 citations

, , +17

Ventilation-perfusion studies in suspected pulmonary embolism

DR Biello, AG Mattar, RC McKnight et al. · American Journal of Roentgenology · 1979 · 317 citations

, , +16